"The pharmaceutical industry is pricing drugs at what the market will bear. Will this cause a back-lash from patients, insurers, and providers?
Ponte Vedra Beach, Florida (PRWEB) January 17, 2013
The most-read story in HealthEconomics.Com HealthCare Value and Market Access News for the week ending January 12, 2012 examined the annual price tag for Gattex, a treatment for short bowel syndrome, at $295,000 per year. The price was based on Gattex marketer’s analysis of competitors, as well as hospitalization costs avoided. The inpatient cost comparison story will be used with payers, and the company found that patients, physicians, and insurers were willing to pay more than what stock analysts initially predicted. Gattex is an orphan drug, designed to reduce intravenous feedings after resection and partial removal of the small intestine, and is the first drug approved for the treatment of small bowel syndrome since 2004. Recent reports indicate that about 3,000 patients will potentially benefit from such treatment.
Another top story on HealthEconomics.Com explored the record number of 39 drug approvals by the Food & Drug Administration (FDA) in 2012, a level not seen since 1996 when 53 new drugs were approved. FDA has been touting their productivity level for meeting or exceeding nearly all PDUFA goals for application review. This story is featured on HealthEconomics.Com News on healthcare trends.
Is a buying spree in store for the pharmaceutical industry? Another frequently-read story explored how big pharma is shoring up their bank balances, and their need to fill revenue gaps left by the patent cliff. One solution the industry appears to be pursuing is to buy companies with high-potential drugs in the pipeline, rather than to wait for their own R&D to produce returns. The story is featured on HealthEconomics.Com Pharmaceutical Industry News.
About HealthEconomics.Com: A pioneer in the field, HealthEconomics.Com is the global authority in healthcare value and pharma market access. Each day, HealthEconomics.Com compiles the latest news, policy updates, resources, conferences, and jobs for BioPharma’s professionals involved in health economics, outcomes research, market access, and pricing. A trusted resource, HealthEconomics.Com’s comprehensive content is carefully selected by a discerning health economist editor, making it the most visited website for healthcare value and market access in the industry, with visitors encompassing all corners of the globe.
News Media interested in receiving the most current information on healthcare value and market access may obtain a free subscription to HealthEconomics.Com Pharmaceutical News by visiting the site or by subscribing to the HealthEconomics.Com Newsletter.